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Abstract
Antibody replacement therapy for patients with antibody deficiencies contains only IgG. As a result, concurrent IgM
and IgA deficiency present in a large proportion of antibody deficient patients persists. Especially patients with IgM
deficiency remain at risk for recurrent infections of the gastrointestinal and respiratory tract. The lack of IgM in the
current IgG replacement therapy is likely to contribute to the persistence of these mucosal infections because this
antibody class is especially important for complement activation on the mucosal surface. We evaluated whether
supplementation with IgM increased serum bactericidal capacity in vitro. Serum was collected from a patient with
agammaglobulinemia and supplemented with purified serum IgM to normal levels. Antibody and complement depo-
sition on the bacterial surface was determined by multi-color flow cytometry. Bacterial survival in serum was
determined by colony-forming unit counts. We present a patient previously diagnosed with agammaglobulinemia
due to CD79A (Igα) deficiency revealing a novel pathogenic insertion variant in the CD79a gene
(NM_001783.3:c.353_354insT). Despite IgG replacement therapy and antibiotic prophylaxis, this patient developed
a Campylobacter jejuni spondylodiscitis of lumbar vertebrae L4–L5. We found that serum IgM significantly con-
tributes to complement activation on the bacterial surface of C. jejuni. Furthermore, supplementation of serum IgM
augmented serum bactericidal activity significantly. In conclusion, supplementation of intravenous IgG replacement
therapy with IgM may potentially offer greater protection against bacterial infections, also in the context of increas-
ing antibiotic resistance.
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Introduction
Patients with agammaglobulinemia have very low or no serum
immunoglobulin levels, making these patients highly suscep-
tible to infections. The largest group of patients has X-linked
agammaglobulinemia (XLA), which is a caused by a defect in
the Btk gene encoding Bruton Tyrosine Kinsase (Btk), which
accounts for 85% of agammaglobulinemia patients. A smaller
group has defects in for instance IGLL1, CD79A, CD79B, or
BLNK, which have clinical findings that are similar from those
seen in patients with mutations in Btk but tend to have a more
severe onset of disease [1].
Treatment relies on the use of IgG replacement therapy
(IgGRT), sometimes in conjunction with prophylactic antibi-
otic use. IgGRT was first introduced in 1952 by Colonel
Ogden Bruton and applied to the first patient with
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agammaglobulinemia [2]. IgGRT is still the main therapy to
date and successfully reduces the frequency of invasive bac-
terial infections in patients with immunoglobulin deficiency
[3]. However, despite IgGRT, agammaglobulinemia patients
still have increased infection rates and lowered life expectancy
[4]. Currently used immunoglobulin preparations contain only
IgG. As a result, concurrent IgM and IgA deficiency present in
a large proportion of antibody deficient patients persists.
Especially patients with IgM deficiency, such as agammaglob-
ulinemia patients, remain at risk for recurrent infections of the
respiratory tract [5]. Gastrointestinal manifestations also pres-
ent a significant burden; 35% of XLA patients suffer from
complications including recurrent infections and inflammato-
ry bowel disease [6]. The lack of especially IgM in the current
IgGRT is likely to contribute to the persistence of these mu-
cosal infections because this antibody class is especially im-
portant for complement activation on the mucosal surface.
Patients with selective IgM deficiency (sIgMD) represent
another model disease where IgM is absent. The immunolog-
ical and clinical phenotype of sIgMD is very heterogeneous,
and patients can even remain asymptomatic [7]. In a series of
17 sIgMD patients, recurrent upper respiratory tract infections
were observed in five out of six patients with undetectable
IgM levels (< 0.05 g/L) [7]. Patients with sIgMD can also
present with invasive manifestations such as sepsis and men-
ingitis [8]. Although for most sIgMD patients, IgGRTwas not
required [7]; it is suggested to be beneficial for patients with
recurrent or severe infections [9].
Previous observational work demonstrated an important
protective effect of IgM against colonization of the respiratory
tract by non-typeable Haemophilus influenzae (NTHi) in pa-
tients with hypogammaglobulinemia [10]. We showed that
especially recognition of NTHi lipooligosaccharide by IgM
efficiently increased complement- and neutrophil-mediated
killing [11, 12], which might contribute to the protective effect
of IgM against colonization [10]. We hypothesized that the
superior efficacy of complement activation by IgM compared
to IgG may explain this observation. This may be especially
relevant for protection against mucosal Gram-negative
bacteria.
Here, we describe a patient with a CD79A (Igα) deficiency
due to compound heterozygous mutations in the CD79a gene.
Igα is the signal transduction molecule of the pre-B cell re-
ceptor. Absence of Igα results in a block from pro-B cells to
pre-B cells in the B cell differentiation pathway, resulting in
agammaglobulinemia [1].
We show that IgM supplementation of serum from a
CD79A deficient agammaglobulinemia patient on IgG
substitution therapy increases serum bactericidal activity
against Campylobacter jejuni in vitro. This finding sug-
gests that IgM containing immunoglobulin preparations
may improve protective efficacy compared to the current
IgGRT.
Material and Methods
Ethics Statement
The study was approved by the ethics committee of the
Radboudumc, Nijmegen, the Netherlands. Written informed
consent was obtained from the patient. Collection of blood
from healthy volunteers was approved by the ethics commit-
tee of the Radboudumc, Nijmegen, the Netherlands. All ex-
periments were carried out in accordance with local guidelines
and regulations and comply with the Declaration of Helsinki
and the Good Clinical Practice guidelines.
Serum Preparation and Storage
Blood was drawn in vacutainer gel serum tubes (BD
Biosciences) and kept on ice within 30 min following collec-
tion. Serum was prepared by centrifuging blood for 10 min at
4000×g, and serum aliquots were stored at − 80 °C.
Serum was diluted in HBSS without phenol red containing
Ca2+ and Mg2+ + 0.1% gelatin (Hepes3+). For complement-
inactivation, serum was heat-inactivated (HI) by incubating
20 min at 56 °C. Purified IgM from human serum (Sigma-
Aldrich, I8260) was washed with PBS on a Amicon Ultra-0.5
Centrifugal Filter Unit column (Millipore) to remove the pre-
servative sodium azide and suspended into PBS at a concen-
tration of 1 mg/mL.
Bacterial Growth Conditions and Storage
The patient’s C. jejuni isolate was used for in vitro functional
assays. Bacteria were grown on blood agar plates in a
microaerobic environment at 42 °C. Bacteria were harvested
directly from plate and suspended into PBS containing 16%
glycerol for storage.
Flow Cytometry
Bacteria were washed with Hepes3+ and diluted to an OD620 of
0.1. For IgG, IgM, C3, and C5b9 surface opsonization, 50 μL
bacteria were incubated with 50 μL 10% serum in Hepes3+ for
15 min at 37 °C. Opsonized bacteria were washed, fixed for
20 min with 2% paraformaldehyde, and incubated with 1:500-
diluted C3-specific polyclonal antibody (MP Biomedical,
Cappel), 1:100-diluted C5b-9-specific monoclonal antibody
(Santa Cruz biotechnology), 1:50-diluted Fcγ Fragment
Specific PerCP AffiniPure Goat Anti-Human IgG (Jackson
Immunoresearch), and 1:500-diluted Fc5μ fragment specific
Alexa Fluor® 647 AffiniPure Goat Anti-Human IgM
(Jackson Immunoresearch) in PBS with 2% BSA for 15 min
at room temperature. Bacteria were washed and incubated with
1:200 PE-labeled goat anti-mouse IgG (ThermoFisher
Scientific) in PBS with 2% BSA for 15 min at room
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temperature. Bacteria were washed and suspended in PBS for
flow cytometry using a FACS LSR II instrument (BD
Biosciences). Data were analyzed using the software program
FlowJo version 10.2. Data is presented as geometric mean fluo-
rescence intensity (MFI) in arbitrary units (AU).
Bacterial Survival Assays
Bacteria were washed with Hepes3+ and diluted to a concen-
tration of ∼ 20.000 colony forming units (CFU)/mL. Fifty
microliter of bacteria was mixed with 50 μL serum or HI-
serum diluted in Hepes3+ and incubated 30 min at 37 °C.
Serial dilutions were plated on blood agar plates and incubated
in a candle jar at 42 °C. Survival was determined by dividing
the CFU counts in serum with the CFU count in HI-serum.
Results
Case Report Campylobacter Jejuni Spondylodiscitis
in a Patient with Agammaglobulinemia Associated
with Novel CD79a Pathogenic Insertion Variant
Here, we describe a 16-year-old male, who was diagnosed
with agammaglobulinemia associated with CD79a deficiency
at 2 years of age. Initially, he presented with severe bacterial
pneumonia associated with nasopharyngeal carriage of
Haemophilus influenzae type B. In addition, he suffered from
chronic otitis media with effusion. Initial immunologic assess-
ment demonstrated agammaglobulinemia (IgG < 0.5 g/L, IgA
< 0.13 g/L, and IgM < 0.06 g/L). Immunophenotyping of pe-
ripheral blood revealed total absence of CD19+ B cells. Bone
marrow aspirate showed decreased percentages of CD22+ B
cells (20%, normal < 5 years of age 36 ± 7%), with absence of
CD79A expression. Sequence analysis confirmed the diagno-
sis of CD79a deficiency due to compound heterozygous mu-
tations: in one allele, we found the NM_001783.3:c.380-2A >
G pathogenic variant as described previously [13]; in the sec-
ond allele, we found a novel insertion in exon 2 of a thymine
(c.353insT). This variation creates a frame shift starting at
p.(Cys119Leufs*63). The new reading frame ends in a
STOP codon 63 positions downstream. This is the sixth pa-
tient with CD79a mutations described to date.
After the diagnosis, subcutaneous IgGRT was started and
combined with antibiotic prophylaxis. The patient received
weekly subcutaneous IgG at a dose of 320 mg/kg/28d
(Hizentra; CSL Behring AG, Swiss) (IgG through level 8–
10 g/L) and was on prophylactic amoxicillin 500 mg orally
twice daily. To facilitate travel during summer holidays, sub-
cutaneous IgGRTwas interrupted for maximally 3 weeks at a
time and intravenous IgGRT at a dose of 365 mg/kg/28d was
administered before traveling. The patient had a mild
subsequent clinical course with episodes of gastrointestinal
parasitic infections and chronic conjunctivitis.
At age 16, the patient presented with a 3-week history of
lower back pain without fever. Laboratory evaluation
demonstrated leukocytes of 12.109/L, CRP 37 mg/L, and
ESR 15 mm/h; MRI examination showed spondylodiscitis
of lumbar vertebrae L4–L5. Hewas initially started on empiric
flucloxacillin and gentamicin. Blood culture was positive for a
Campylobacter jejuni strain, which was resistant for tetracy-
cline (8 mg/L), but susceptible to erythromycin/azithromycin
(4 mg/L) and ciprofloxacin (0.125 mg/L) according to the
EUCASTcriteria. The strain was additionally tested for amox-
icillin (256 mg/L, resistant) and amoxicillin-clavulanic acid
(2 mg/L, susceptible), which indicates the presence of beta-
lactamase activity. The patient was switched to azithromycin
500 mg once daily and treated orally for 9 months in total with
good clinical recovery. As preferred by the patient, IgGRTwas
switched from subcutaneous to intravenous at 500 mg/kg/
28 days. Additional tests of complement function showed
normal classical (CH50 102% (67–149%)) and alternative
pathway (AP50 68% (67–133%)) activity. Since patients with
agammaglobulinemia receiving IgGRT only have corrected
IgG serum levels, we evaluated whether supplementation with
serum IgM increased serum bactericidal capacity in vitro.
Campylobacter Jejuni-Specific IgG at Different IgG
Concentrations
Six months previous to presentation with spondylodiscitis,
subcutaneous IgGRT was briefly interrupted for summer
holidays, while the patient was protected with an equal dose
intravenous IgG. Serum samples were taken before and after
intravenous IgG administration as part of a research proto-
col. IgG, IgA, and IgM serum levels were determined, and
IgG concentration was 8.08 g/L pre-intravenous IgG, and
14.8 g/L post-intravenous IgG, but both samples were with-
in normal range (5.2–15.6 g/L), whereas IgA and IgM con-
centrations were below the detection limit in both samples
(< 0.07 g/L).
To determine the capacity of the patient’s low- and high-
concentration IgG serum to opsonize C. jejuni, we incubated
the bacteria with 5% low- and high-concentration IgG serum
followed by detection of IgG, IgM, complement factor 3 (C3),
and membrane attack complex C5b9 opsonization by flow
cytometry (Fig. 1a). Despite the large difference in IgG levels
in the low- and high-concentration IgG samples, similar IgG
opsonization of the bacterial surface (412 ± 73 and 462 ± 111,
respectively) was detected, whereas IgM was absent (Fig. 1b,
c). As functional read out for complement activation, we de-
termined C3 and C5b-9 deposition on the bacterial surface. In
accordance with IgG opsonization, no differences between
low- and high-concentration IgG serum for C3 (11.043 ±
2.818 and 10.840 ± 3.183, respectively) or C5b-9 (1.011 ±
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Fig. 1 Similar recognition of Campylobacter jejuni by IgG low- and
high-concentration IgG patient serum. Bacteria were incubated with
5% low- and high-concentration IgG patient serum, stained for IgG,
IgM, C3, and C5b9 and subjected to flow cytometry. a Flow cytometry
gating strategy. Opsonization with IgG (b), IgM (c), C3 (d), and C5b9 (e)
was determined by flow cytometry. Measurement of geometric mean
fluorescence intensity (MFI) was depicted in arbitrary units (AU (n = 6,
mean ± standard error of the mean). A two-way paired Student t test was
used for statistical analysis. NS not significant
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281 and 738 ± 214, respectively) were detected (Fig. 1d, e).
These data indicated that the patient’s C. jejuni strain was
recognized by IgG present in low- and high-concentration
IgG serum, which was able to activate complement. Based
on these data, we concluded that bactericidal activity of the
low- and high-concentration IgG serum was similar.
Augmented Complement Activation and Serum
Killing of Campylobacter Jejuni with Serum IgM
Supplementation
We determined whether IgM supplementation would improve
complement activation and bactericidal activity against
C. jejuni. For these experiments, a pool of low- and high-
concentration IgG serum was used as patient serum and serum
from four healthy individuals was included as normal reference.
Wemeasured IgG and IgMopsonization of the bacterial surface
with 5% patient serum with or without IgM supplementation
(5 mg/dL IgM in 5% serum, equivalent for 100 mg/dL IgM in
normal serum). Opsonization with IgG was similar for 5% pa-
tient serum with or without IgM (369 ± 56 and 479 ± 92, re-
spectively), which was within the normal range found for four
healthy individuals (363 ± 70, range 208–521) (Fig. 2a).
Opsonization with IgM was absent with patient serum and
clearly present with patient serum supplemented with IgM
(1.952 ± 502), which reached the normal range found for four
healthy individuals (1.908 ± 48, range 1.803–1.993) (Fig. 2b).
Although IgG in serum alone was able to activate complement
as determined by C3 deposition on the bacterial surface, sup-
plementation of IgM augmented C3 opsonization significantly
(7.317 ± 2.805 to 24.295 ± 1.521), which reached levels close
the levels found for four healthy individuals (27.877 ± 1.665,
range 25.263–32.551) (Fig. 2c). Similarly, increased C5b9 de-
position in the presence of IgM was observed (606 ± 123 to
3.736 ± 421), which was well within to the normal levels found
for four healthy individuals (3.509 ± 347, range 2.612–4.133)
(Fig. 2d). This increased complement activation was also rep-
resented in increased serum bactericidal activity because serum
survival of C. jejuni in 2, 5, or 10% serum was significantly
decreased with IgM supplementation (Fig. 2e).
Discussion
Immunoglobulin replacement therapy was introduced by
Colonel Ogden Bruton and applied to the first patients with
agammaglobulinemia in 1952 [2] and remains the main ther-
apy to date. Despite immunoglobulin therapy, agammaglobu-
linemia patients have increased infection rate and lowered life
expectancy [4]. There have been no major advancements
aside from subcutaneous immunoglobulin therapy in the early
1980s [14]. Recent advances in therapy for patients with
agammaglobulinemia are mostly found in gene therapy [15,
16]. Although these methods show great potential, these are
still far from being applied. Therefore, limiting infections and
thereby increasing patient’s quality of life by supplementing
IgM to IVIG would be an attractive alternative.
Campylobacter infections are frequently observed in patients
with hypogammaglobulinemia, mainly causing gastrointestinal
infections, despite IgGRT [17]. Besides frequent mucosal infec-
tions, Campylobacter species are also seen to cause bacteremia
[18–20] and atypical infections in patient with agammaglobulin-
emia, including erysipelas-like skin lesions [19], arthritis [21],
pericarditis [22], cellulitis [23], and spondylodiscitis (current re-
port). Secretory IgA may act as an important local immune de-
fense; however, there is no significant increase ofCampylobacter
infections in patients with selective IgA deficiency [17].
Therefore, concurrent IgM deficiency might decrease risk for
bacterial infections because this class of antibody is especially
good in complement fixation on bacterial pathogens.
Here, we show augmented serum bactericidal activity medi-
ated by human serum IgM, which might increase protection
against bacterial infections. Though C3 opsonization on bacteria
may partly be explained by alternative complement pathway
activation, our data indicate that IgM-mediated classical comple-
ment pathway activation is an important determinant. Our results
support the use of IgM-enriched IgGRT in patients with IgG
deficiency and concurrent IgM deficiency. For example,
Borleffs and colleagues successfully treated two
hypogammaglobulinemia patients with persistent gastro enteric
C. jejuni infections [24]. Six dosages of Pentaglobin, an IgM-
enriched intravenous IgG preparation containing 12% IgM and
12% IgA, at 3-week intervals increased bactericidal activity
against C. jejuni, was well tolerated, and there were no culture-
confirmed relapses of C. jejuni infections [24]. Pentaglobin was
shown to contain both IgG and IgM antibodies recognizing
C. jejuni outer membrane proteins [25]. In addition, two patients
with relapsing Campylobacter jejuni infections were given fresh
frozen plasma, which contains IgA and IgM, for 2 or 4 weeks
(500 mL twice weekly) and resulted in cure in both patients [19].
Plasma infusion resulted in detectable serum IgA levels in two
patients and detectable serum IgM levels in one patient [19].
The use of IgM-enriched intravenous IgG preparation
Pentaglobin has been tested in different patient groups with
variable results. Pentaglobin was shown to significantly re-
duce mortality in patients with sepsis [26, 27], but this was
not corroborated by another study [28] or for critical illness
polyneuropathy and/or myopathy patients with multi organ
failure and sepsis [29]. Prophylactic use of IgM-enriched
intravenous IgG preparation Pentaglobin has been tested
in adults and pediatric patients after hematopoietic stem cell
transplantation. In adults, a reduction in risk of dying of an
infection after bone marrow transplant was observed [30].
However, in pediatric patients, no significant beneficial ef-
fects were observed [31]. A 2013 Cochrane database review
concluded that the trials were too small and the totality of
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the evidence is still insufficient to support robust conclu-
sions [32].
A beneficial effect of Pentoglobin in comparison to con-
ventional intravenous IgGRT is its effective reduction of en-
dotoxin [33, 34]. Direct effects on bacterial killing are also
observed. Pentaglobin had a greater opsonic activity against
Pseudomonas aeruginosa, Klebsiella pneumoniae, and
Escherichia coli, in comparison to intravenous IgG
Sandaglobulin [35]. Pentaglobin showed augmented in vitro
killing of Staphylococcus aureus, E. coli, and P. aeruginosa,
but slightly reduced killing K. pneumoniae and Enterococcus
faecium, in comparison to intravenous IgG Intratect [36]. In a
S. aureus mouse sepsis model, the number of bacteria in liver
and kidneywas significantly lower for animals receiving IgM-
enriched IVIG Pentaglobin in comparison to animals receiv-
ing IVIG Intratect [36].
Recent advances in IgM-enriched immunoglobulin thera-
py, Trimodulin (BT-588, predecessor BT-086) containing
more IgM (23%), in comparison to Pentaglobin (12%) are
promising [37, 38], and a clinical trial in patients with severe
pneumonia is underway [39]. Since IgM concentration present
in Trimodulin is higher, we expect a strong additive effect on
Fig. 2 Serum IgM augments
complement deposition on the
bacterial surface and serum
killing of Campylobacter jejuni.
Bacteria were incubated with 5%
patient serum with or without
supplementation of IgM or 5%
serum from healthy controls.
Opsonization with IgG (a), IgM
(b), C3 (c), and C5b9 (d) was
determined by flow cytometry.
Measurement of geometric mean
fluorescence intensity (MFI) was
depicted in arbitrary units (AU
(n = 6, mean ± standard error of
the mean). A one-way ANOVA
with Dunnett’s Multiple
Comparison Test was used for
statistical analysis. NS not
significant; **P < 0.01;
***P < 0.001. (e) Bacterial
survival in 2, 5, or 10% patient
serum with or without
supplementation of IgM was
determined after 30 min (n = 4,
mean ± standard error of the
mean). A two-way ANOVAwith
Bonferroni post hoc test was used
for statistical analysis.
***P < 0.001
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bacterial killing. It remains to be determined whether subcu-
taneous administration of IgM containing products offers suf-
ficient bioavailability.
In conclusion, we show that supplementation of human
serum IgM significantly contributes to complement activation
on the bacterial surface and increases serum bactericidal ac-
tivity. Therefore, supplementation of IgGRT with IgM may
potentially offer greater protection against bacterial infections,
which is also relevant in the context of rising antibiotic resis-
tance. This hypothesis needs to be further tested in clinical
studies.
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